2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3426 Interferon-α-2b as maintenance therapy eradicate measurable residual disease and improves outcomes in MRD positive favorable-risk acute myeloid leukemia

Wenbing Duan, Qi Chen2, Wen-Jing Yu, MD3, Xiaolu Zhu, MD4, Hong-Xia Shi5, Ya-Zhen Qin6, Xiaosu Zhao7, Guorui Ruan, PhD8, Ying-Jun Chang9, Xiaojun Huang, MD,PhD10, Hao Jiang11
1 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease,, Beijing, China
2 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, China
3 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease,, Beijing, China
4 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, China
5 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease,, Beijing, China
6 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease,, Beijing, China
7 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, China
8 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease,, Beijing, China
9 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease,, Beijing, China
10 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, China
11 Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, China

Background

Relapse is a major challenge for favorable-risk acute myeloid leukemia (AML) , especially in patients with persistent measurable residual disease (MRD). Maintenance therapy is essential to prevent relapse, and now is recommended for patients irrespective of chemotherapy intensity. Oral azacitidine, azacitidine or decitabine are recommend for the maintenance in favorable-risk AML except core banding factor AML(CBF-AML). Our previous study reveled interferon-α-2b (IFN-α-2b) maintenance induced MRD eradicated in 78.6% (18/23) favorable-risk AML patients with positive MRD, compared with a spontaneous MRD clearance rate of 26.7%(4/15) in the non-maintenance cohort. We conducted this study to verify the effect of IFN-α-2b as maintenance therapy in favorable-risk AML patients with positive MRD.

 

Methods

This prospective, single-arm cohort study was conducted in AML adults in favorable-risk group with positive MRD at the end of consolidation who received IFN-α-2b as maintenance therapy. (ChiCTR2000035310). Upon completion intensive consolidation therapy, patients with positive MRD received IFN-α-2b at a dose of 3 million IU tree times a week for a planned duration of 1.5 to 2 years. MRD were monitored by real-time quantitative reverse transcription in patients with RUNX1::RUNX1T1, CBFβ::MYH11 and NPM1 mutation. MRD levels were calculated as a percentage of RUNX1::RUNX1T1 or CBFB::MYH11 transcript copies/ABL copies or NPM1 mutant copy number/ABL copies. The sensitivity of MRD detection reached 10-5. In patients carrying CEBPA bzip mutation, MRD assessment was performed via flow cytometry. The primary endpoint was the relapse rate, encompassing hematologic and molecular relapse. Event-free survival (EFS) and overall survival (OS) were calculated from the initiation of maintenance therapy.

Results

Between June 2018 and February 2026, the time of initiation of IFN-α-2b, a total of 50 patients were included. The median age was 47 (range 18-68) years, and 60%(30/50) were male. The distribution of AML genotypes was as follows: RUNX1::RUNX1T1 60% (30/50), CBFβ::MYH11 34% (17/50), NPM1 mutation 4% (2/50), and CEBPA bzip mutation 2% (1/50). After a median of 6 (4-8) cycles of consolidation therapy, patients initiated IFN-α-2b as maintenance therapy. Median transcription level at post-consolidation were 0.0115(0.0025-0.110)% in RUNX1::RUNX1T1 group and 0.016(0.0029-0.056)% in CBFβ::MYH11 group, respectively. The corresponding transcript level were 0.004% and 0.010% in the two patients with NPM1 mutation.

The median interval from diagnosis to the initiation of IFN-α-2b was 11.2 (7.1-29.4) months, and maintenance therapy last for 17.6 (1.9-32.0) months. After a median of 2.6 (0.9-25.7) months of maintenance, 68% (34/50) patients achieved MRD negativity. The 1-year cumulative rate of MRD clearance was 76%(95%CI: 61-91). The overall hematologic relapse rate was 8%(4/50) and the molecular relapse rate was 28% (14/50); during maintenance therapy along, these corresponding rates were 8% (4/50) and18% (9/50), respectively. Additionally, 12%(6/50) patients underwent allogeneic hematopoietic stem cell transplantation. With a median follow-up time of 31.9(2.7-94.2) months starting from maintenance therapy initiation, median EFS and OS were not reached.

The 3-year EFS rate and 3-year OS rate was 57.0% (95%CI 41.7-72.3) and 95.7% (95%CI 90.0-100) respectively from the initiation of maintenance therapy. Regarding adverse events, thyroid dysfunction was observed in 2%(1/50) patients, grade 1-3 hepatotoxicity occurred in 6%(3/50) patients, and one patient developed hepatitis E. One patient ceased IFN-α-2b treatment because of intolerable cutaneous rash.

KIT mutation were detected in 17%(5/30) of patients with RUNX1::RUNX1T1, none of which were D816 mutation. In the CBFβ::MYH11 patients cohort, 12%(2/17) harbored KIT mutation, and both were D816 mutation. The rate of MRD clearance from positive to negative was comparable between the two  CBF-AML groups [67%(20/30) vs. 76%(13/17), p = 0.480]. Furthermore, no significant differences were observed between the two groups in EFS (3-year EFS rate 60.9% vs.61.2%, p = 0.857) and OS (3-year OS rate 92.6% vs.100%, p = 0.257).

Conclusion

Our results indicated IFN-α-2b as maintenance therapy facilitates eradication of MRD which was a key driver of relapse in MRD positive favorable-risk AML, particularly in CBF-AML, which was also consistent with the findings in our previous retrospective study.
Wenbing Duan: No relevant conflicts of interest to declare.